MARKET

ANL

ANL

Adlai Nortye Ltd.
NASDAQ
7.95
-0.41
-4.90%
After Hours: 7.80 -0.15 -1.89% 16:19 03/13 EDT
OPEN
8.08
PREV CLOSE
8.36
HIGH
8.82
LOW
7.73
VOLUME
154.28K
TURNOVER
--
52 WEEK HIGH
12.09
52 WEEK LOW
0.8786
MARKET CAP
419.56M
P/E (TTM)
-13.8550
1D
5D
1M
3M
1Y
5Y
1D
Adlai Nortye files to sell $600M of Class A ordinary shares
TipRanks · 4d ago
Adlai Nortye files to sell 64.62M Class A ordinary shares for holders
TipRanks · 4d ago
Weekly Report: what happened at ANL last week (0302-0306)?
Weekly Report · 5d ago
Weekly Report: what happened at ANL last week (0223-0227)?
Weekly Report · 03/02 09:22
Adlai Nortye to Participate in Leerink Partners Global Healthcare Conference 2026
Reuters · 03/02 06:57
Weekly Report: what happened at ANL last week (0216-0220)?
Weekly Report · 02/23 09:22
Weekly Report: what happened at ANL last week (0209-0213)?
Weekly Report · 02/16 09:22
Adlai Nortye Price Target Announced at $16.00/Share by HC Wainwright & Co.
Dow Jones · 02/13 17:37
More
About ANL
Adlai Nortye Ltd. is a global clinical-stage biotechnology company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor and AN4035, a Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5).

Webull offers Adlai Nortye Ltd (ADR) stock information, including NASDAQ: ANL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANL stock methods without spending real money on the virtual paper trading platform.